自2019年起，全球正经历一场新型冠状病毒——严重急性呼吸综合征冠状病毒（SARS-CoV）2的爆发。该病毒的全球传播对公共卫生构成了严重挑战，世界卫生组织宣布该爆发为国际关注的公共卫生紧急事件。截至2023年6月8日，该病毒的迅速传播已导致全球超过7.67亿人感染和6.94百万人死亡。与先前的SARS-CoV-1和中东呼吸综合征冠状病毒爆发不同，COVID-19爆发在感染者中导致了较高的死亡率；这是由多器官衰竭所引起的，其原因可能是由于SARS-CoV-2在多个器官中广泛存在的血管紧张素转换酶2（ACE2）受体。癌症患者可能对COVID-19特别容易感染，因为癌症治疗（如化疗、免疫疗法）会抑制免疫系统。因此，患有癌症和COVID-19的患者可能预后不佳。了解如何管理可能感染SARS-CoV-2的癌症患者的治疗至关重要。治疗决策必须根据个案情况做出，并且在COVID-19爆发期间需要对患者进行分层。在这里，我们回顾了癌症患者中COVID-19的管理，并重点关注了在受癌症影响的器官或组织以及肿瘤分期的基础上应采取的措施。© 2023. 作者个人以独家许可给Springer-Verlag GmbH Germany，属Springer Nature的一部分。

Since 2019, the world has been experiencing an outbreak of a novel beta-coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV)-2. The worldwide spread of this virus has been a severe challenge for public health, and the World Health Organization declared the outbreak a public health emergency of international concern. As of June 8, 2023, the virus' rapid spread had caused over 767 million infections and more than 6.94 million deaths worldwide. Unlike previous SARS-CoV-1 and Middle East respiratory syndrome coronavirus outbreaks, the COVID-19 outbreak has led to a high death rate in infected patients; this has been caused by multiorgan failure, which might be due to the widespread presence of angiotensin-converting enzyme 2 (ACE2) receptors-functional receptors of SARS-CoV-2-in multiple organs. Patients with cancer may be particularly susceptible to COVID-19 because cancer treatments (e.g., chemotherapy, immunotherapy) suppress the immune system. Thus, patients with cancer and COVID-19 may have a poor prognosis. Knowing how to manage the treatment of patients with cancer who may be infected with SARS-CoV-2 is essential. Treatment decisions must be made on a case-by-case basis, and patient stratification is necessary during COVID-19 outbreaks. Here, we review the management of COVID-19 in patients with cancer and focus on the measures that should be adopted for these patients on the basis of the organs or tissues affected by cancer and by the tumor stage.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.